androgen receptor variant 7 (AR-V7) has been suggested as potential marker for treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC). The aim of the present review is to critically analyze: frequency of the AR-V7 expression in mCRPC cases—impact of AR-V7 expression on abiraterone, enzalutamide, and taxane therapy.

AR-V7 is an important oncogenic driver and plays a role as an early diagnostic and prognostic marker, as well as a therapeutic target for antagonists such as niclosamide and TAS3681. Anti-AR-V7 drugs have shown promise in recent clinical investigations on this subset of patients.

AR-V7 expression in circulating tumor cells has been associated with poor outcomes in patients treated with second- and third-line AATTs. Clinically validated assays are now commercially available for the AR-V7 biomarker.

2014年9月11日 · We hypothesized that detection of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate cancer would be associated with resistance to...

2021年9月21日 · Identifying novel drugs that can trigger the degradation of AR-V7 is therefore critical to cure CRPC. Here we show that nobiletin, a polymethoxylated flavonoid derived from the peel of Citrus...

2020年2月1日 · AR-V7 expression in circulating tumor cells has been associated with poor outcomes in patients treated with second- and third-line AATTs. Clinically validated assays are now commercially available for the AR-V7 biomarker.

2021年7月16日 · Here, we identify a novel AR/AR-V7 degrader (ARVib) and found that ARVib effectively degrades AR/AR-V7 protein and attenuates AR/AR-V7 downstream target gene expression in prostate cancer cells....

Androgen receptor splice variant 7 (ARV-7) is a resistance mechanism to hormonal therapy in metastatic castrate-resistant prostate cancer (mCRPC). It has been associated with poor outcomes. On progression to castrate resistance, ARV-7 positivity has been identified in global populations at an incidence of 17.8%-28.8%.

2024年5月5日 · In this study, we propose a pathway in next-generation anti-androgen resistance and prostate cancer progression: a) inhibiting AR function or nuclear translocation by binding to any or multiple domains of the AR and ARV7 protein; b) degrading the AR and ARV7 protein to prevent any inadvertent activation by any of the abovementioned alternate mec...

2019年3月3日 · Presence or absence of androgen receptor (AR) splice variants, AR-V7 and AR v567es, in mCRPC patient circulating tumor cells (CTCs) may be associated with taxane treatment outcomes. A novel digital droplet PCR (ddPCR) assay assessed AR splice variant expression in CTCs from patients receiving docetaxel or cabazitaxel in TAXYNERGY ( NCT01718353 ).